And they're using 25% discount date for their base case plus applying the Phase progression probabilities - they have revenue in the mid-2020's in the billions, so the upside for passing time and hurdles is a multiplier at each Phase completion plus 25% upside per annum. Worth reading through the whole report IMO because all of the calculations and reasoning are fully laid out.
Ann: SRC Approves Commencement Of Fourth And Final Cohort Dosing, page-12
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
77.0¢ |
Change
-0.055(6.67%) |
Mkt cap ! $95.24M | |||
| Open | High | Low | Value | Volume |
| 83.0¢ | 83.0¢ | 75.0¢ | $223.5K | 283.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 23353 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.5¢ | 1100 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| AGN (ASX) Chart |